Bioiatriki Group reports positive financial results for 2025

In late July 2026, the Bioiatriki Group announced its financial results for the 2025 fiscal year, reflecting a period of significant growth and operational improvement. The company, which has maintained a presence in the Cypriot primary healthcare sector—specifically clinical laboratories and imaging centers—since 2017, saw a substantial increase in turnover and profitability.

Key performance indicators highlight a doubling of Adjusted EBITDA and a return to significant net profits. Turnover before rebate and claw-back mechanisms rose by 5% to reach 200.9 million euros, while turnover after these deductions increased by 12% to 159.4 million euros. Additionally, the Group reported a strengthened cash position and a drastic reduction in total debt. These improvements follow a strategic shift initiated in 2024, which prioritized innovation, digitalization, advanced management systems, and high-quality health services.

The Group expects this positive trajectory to accelerate in the coming years as it continues its expansion and operational efficiency programs. The current financial standing underscores the effectiveness of the recent corporate restructuring efforts and investments in new technologies.